MedTrace Logo

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

NCT02235272 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 339

Last updated 2017-01-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.

Conditions

Interventions

DRUG

XG-102

Comparison of XG-102 versus placebo sub-conjunctival injection efficacy

DRUG

Placebo

comparison of XG-102 versus placebo sub-conjunctival injection efficacy

Sponsors & Collaborators

  • Xigen SA

    lead INDUSTRY

Principal Investigators

  • Steven M Silverstein, MD · Silverstein Eye Centers

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02235272 on ClinicalTrials.gov